Anti-t lymphocyte immunoglobulin for human use, rabbit : List of nationally authorised medicinal products - PSUSA/00010252/202406

Human medicines European public assessment report (EPAR): Sondelbay, teriparatide, Date of authorisation: 24/03/2022, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Efient, prasugrel, Date of authorisation: 24/02/2009, Revision: 28, Status: Authorised

Human medicines European public assessment report (EPAR): Incruse Ellipta (previously Incruse), umeclidinium bromide, Date of authorisation: 28/04/2014, Revision: 22, Status: Authorised

Human medicines European public assessment report (EPAR): Lynozyfic, linvoseltamab, Date of authorisation: 23/04/2025, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Zyclara, imiquimod, Date of authorisation: 23/08/2012, Revision: 17, Status: Authorised

Human medicines European public assessment report (EPAR): Pylclari, piflufolastat (18F), Date of authorisation: 27/11/2023, Revision: 6, Status: Authorised

Agenda - PDCO agenda of the 22-25 July 2025 meeting

Human medicines European public assessment report (EPAR): Kaftrio, ivacaftor,tezacaftor,elexacaftor, Date of authorisation: 21/08/2020, Revision: 30, Status: Authorised

Agenda – Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) - 23 July 2025